ABSTRACT
Experimental leprosy studies using Mycobacterium leprae inoculum isolated from a sooty mangabey monkey (SMM) resulted in the accidental discovery that SMM's asymptomatically carry simian immunodeficiency virus (SIV) that is pathogenic in macaques. We showed that the SMM virus, SIVDelta, was antigenically related to SIVmac, which had been identified in macaques, and to the human immunodeficiency virus (HIV). Similar asymptomatic natural SIV infections had been reported in African green monkeys (AGM). Our results together with observations of others led us to propose that both SIVmac and SIVDelta originated in SMM and that HIV emerged in humans as a result of early African nonhuman primate SIV trans-species infections in humans.
INTRODUCTION
Scientific discoveries are often the direct result of planned, systematic research aimed at testing hypotheses derived from prior systematic studies and observations. Frequently, however, discoveries are the result of a convoluted pathway that could not have been predicted or hypothesized. These latter types of discoveries can be the result of serendipity compounded by serendipity. The discoveries that captive sooty mangabey monkeys (SMM) carry asymptomatically an immunodeficiency-inducing virus that is related to the human immunodeficiency virus (HIV), that this virus was inadvertently transmitted to macaques years before its existence or origin was known, and that the passage of this virus was sometimes linked to transmissible lymphomas, fall into this latter category of the scientific process. The fact that our contribution to these discoveries was a by-product of studies of natural and experimental leprosy in SMM's is indicative of the serendipitous nature of the results.
LEPROSY STUDIES
In September, 1979, a female sooty mangabey monkey (SMM) (Cercocebus atys) housed at the Gulf South Research Institute (GSRI), New Iberia, LA, was noted as having severe skin infiltrations that had the appearance of leprosy. She had never been inoculated with an infectious agent and had been a control for a dietary cholesterol study. This SMM, AO15 or "Louise", was transferred to the Delta Regional Primate Research Center (DRPRC) (now the Tulane National Primate Research Center), Covington, LA, in December, 1979. "Louise" might have been euthanized except for the serendipitous fact that Dr. Peter Gerone, the DRPRC Director at that time, was a member of the GSRI Board of Directors and learned by that channel that the animal appeared to have leprosy. There was an on-going tuberculosis study in progress and considerable interest in mycobacterial diseases at the DRPRC at that time. Therefore, Dr. Gerone arranged for the transfer of "Louise" to our Center for further study. She was a feral monkey, approximately five years of age, that had been imported from West Africa in 1975.
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progressive disease was noted (1) . Clinical, immunologic, pathologic and microbiologic studies of the etiologic agent, including DNA identification by Dr. Tomatsu Imaeda, confirmed multibacillary leprosy caused by Mycobacterium leprae that could not be distinguished from human-origin M. leprae (1) . These results caused much excitement among leprosy researchers because natural leprosy had never been observed previously in a monkey (1, 2) . Moreover, a non-human primate model for leprosy had been sought for decades without notable success (2) . If the SMM species could be shown to be uniquely susceptible to experimental leprosy, an important model that closely resembled human leprosy might be at hand.
As chance would have it, the YERKES Primate Center in Atlanta, GA had an active breeding colony of sooty mangabey monkeys, and were willing to ship a few normal animals to the DRPRC for experimental inoculation with M. leprae isolate from A015 and for use as controls. This was a fortunate turn of events because there was no other significant breeding colony of SMM in the world and importers were seldom able to obtain SMM. One reason for this unavailability was that the SMM was not in demand for experimental use or for other purposes and, therefore, methods of trapping them had not been widely implemented. Another reason was that the SMM was the favorite food monkey in West Africa and, therefore, were usually shot rather than captured. Surviving baby SMM were often taken home as "pets", where cross-speciesexposure to numerous human and SMM pathogens was possible. If buyers for these young animals were available, they would be sold to the highest bidder. The few SMM that were commercially exported out of Africa, such as "Louise", were most likely obtained as youngsters by the described pathway.
Briefly, the ensuing experimental M. leprae inoculations at the DRPRC using inoculum originating in A015 were successful and led to many years of fruitful studies of leprosy using the SMM model and other nonhuman primate species . Virtually all inoculated SMM developed leprosy and at least 80% of them developed the more severe LL form that is indicative of little or no cellular immunity to M. leprae antigens (3,39).
SMM TO RHESUS MACAQUE LEPROSY TRANSMISSIONS
After it was established that Mycobacterium leprae was the etiologic agent causing leprosy in A015 and that leprosy could be easily transmitted from one SMM to another, it was considered possible that a monkey-or SMM-adapted strain of M. leprae was responsible, since it had not been previously possible to experimentally transmit leprosy to monkeys using M. leprae isolated from humans (2). Why was it so easy to transmit leprosy in SMM if not due to strain adaptation? In order to test the possibility of strain adaptation, and because rhesus monkeys were much more plentiful than SMM, we inoculated two rhesus monkeys in December, 1980 with M. leprae directly from A015 and, in November, 1982, four were inoculated with an isolate from a SMM (A022) that had been previously inoculated with A015 M. leprae isolate (Table 1) Table 1 ). The other two rhesus (B748 and B845) failed to develop leprosy ( Table 1) . One of the two rhesus monkeys inoculated in 12/80 (A125) was given 1.5 X 10 8 A015 M. leprae by iv route and 6 X 10 8 ic. A125 developed LL leprosy within 20 months. The other monkey (A491) was inoculated with 6 X 10 8 M. leprae from A015 by ic route only. This monkey did not show signs of leprosy by 38 months (Table 1) . A491 was subsequently re-inoculated by iv and ic routes with M. leprae isolated from SMM A022. A491 developed borderline (BB) leprosy 47 months after re-inoculation. Unexpectedly, three of the four rhesus monkeys that developed leprosy in this study (8664, B988 and A491) also developed a wasting syndrome that involved weight loss, diarrhea and death, similar to symptoms described in reports of rhesus monkeys with simian acquired immunodeficiency syndrome (SAIDS) ( Table 1) (31, 40, 41) . Each of the three SAIDS-positive rhesus monkeys received M. leprae inoculum from SMM A022 ( Table 1 ). Figure 1 . Rhesus monkeys 8664, B988, B845 and B748 were inoculated iv and ic with M. leprae inoculum taken from homogenized cutaneous lepromatous (LL) leprosy lesions of SMM A022. Rhesus 8664 and B988 developed leprosy and SAIDS. Rhesus B845 and B748 remained clinically normal. Rhesus 8664 developed lymphoma (asterisks). In an attempt to transmit lymphoma, inoculum was prepared from spleen cell suspensions and the retroorbital lymphoma tissue of 8664 and these suspensions were passaged into rhesus monkeys C638 and C421 (spleen cells ) and B670 and C344 (lymphoma cells). Cells from an abdominal tumor of 8664 were inoculated into rhesus D915 and D930. Only D915 developed lymphoma. Tumor cells or spleen cells from D915 were serially passaged into rhesus D430 and D913 and D589 and D704, respectively, none of which developed lymphoma. All but 3 of the rhesus monkeys described (B845, B748 and C344) developed SAIDS-like symptoms resulting in death (indicated by black dots). {Figure reproduced (31) with permission from the publisher}.
TRANSMISSIBLE LYMPHOMA AND SAIDS
It was at this point that a digression took place during the evolution of the leprosy study. Rhesus monkey 8664 developed a B-cell lymphoma, recognized in March, 1984 ( Table 1 ). The lymphoma was found to be periorbital and was found in other tissue locations at necropsy (31). The other five rhesus monkeys described in Table 1 did not develop lymphoma .
Rhesus 8664 was euthanized in August, 1984 and cell suspensions from the retro-orbital tumor, an abdominal tumor mass or spleen were inoculated into six rhesus monkeys, including D915, which also developed a B-cell lymphoma (Figure 1) (31) . Moreover, the transmissible Bcell lymphoma was found to be associated with an EBVlike herpes virus (42) , similar to reports of lymphomainducing EBV-like viruses from other nonhuman primate species (43, 44) . Lymphoid (spleen) cells or tumor cells from D915 were sub-inoculated into four rhesus monkey recipients (31). These four, as well as five of six rhesus inoculated from 8664, developed clinical symptoms such as weight loss, diarrhea and death, but did not develop lymphoma (Figure 1 ). At necropsy, the rhesus monkeys in this study that succumbed, as well as those that died in the study described in Table 1 , were found to have a variety of signs recognized to be characteristic of SAIDS (31, 40, 41) . At this time, a possible link between experimental transmission of rhesus lymphoma tissue and SAIDS had been suggested (45) . Some studies showed that SAIDS could be transmitted using cell-free inoculum from macaque lymphoma, although lymphoma was not transmitted (46) . SAIDS could be transmitted in macaques using supernatants from homogenized tissues, whole blood and plasma from type D retrovirus-positive macaques (47, 48) . Other laboratories isolated type D retrovirus from macaques (47) (48) (49) (50) and showed that this virus could produce experimental SAIDS (48, 51, 52) . These results were similar to those observed in our studies (Table 1 & Figure 1 ).
By 1985, concurrent with our investigations, reports appeared describing a new retrovirus, termed simian T lymphotrophic virus-IIImac (STLV-IIImac, now known as SIVmac), due to its similarity to the human T lymphotrophic virus-III {HTLV-III, now known as human immunodeficiency virus (HIV)} (53-55). STLV-IIImac transmitted a SAIDS-like disease after inoculation of rhesus macaques (56). Reported electron microscopic morphology (53) and the immunosuppressive properties of STLV-IIImac were remarkably similar to the unknown virus from rhesus 8664 and D915 observed by Drs. Rangan and Baskin in our laboratory (31,42). Inoculum used for rhesus monkeys 8664 and D915 originated in SMM A022 (31). Type D retrovirus could not be detected in our macaques infected with inoculum from SMM A022 (31). Thus, the virus observed in our transmissible lymphoma studies differed from type D retrovirus, but had similarities to STLV-IIImac observed in rhesus monkeys by others.
SMM ORIGIN of SIV
Dr. Michael Murphey-Corb joined our faculty at the DRPRC in 1980. Her retrovirologic training and experience soon led to proof of our growing suspicions that the virus involved in the induction of SAIDS-like disease that occurred during our transmissible lymphoma studies originated in asymptomatic SMM and that it represented a previously unrecognized simian immunodeficiency virus (32). Dr. Murphey-Corb, in conjunction with Dr. Louis Martin, showed by Western blot and ELISA that antibodies cross-reactive with HTLV-III were present in the rhesus monkeys previously inoculated with leprosy inoculum isolated from SMM A022 (32). Moreover, evidence for the presence of this virus was found in 14 of 32 asymptomatic SMM, including SMM A022, the source of our rhesus inoculum (32). The data indicated that the SMM virus, termed STLV-IIIDelta (now SIVDelta), was antigenically related to HTLV-III (now HIV) and the newly described STLV-IIImac (now SIVmac)
M. LEPRAE/SIV INTERACTIONS
With the foregoing in mind, we may now return to a discussion of the leprosy study. As described above, two of four rhesus monkeys inoculated with M. leprae inoculum from SMM A022 (8664 and B988) developed both leprosy and SAIDS, whereas, two (B748 and B845) developed neither disease (Table 1) B988 and B845 became serologically positive for STLVIIIDelta antibody, but B748 failed to seroconvert. It is not known why B748 failed to become infected with STLVIIIDelta (or M. leprae) or why B845 failed to develop clinical SAIDS (or leprosy). B748 died of acute gastric dilatation 4 years post-inoculation. B845 survived for almost 12 years with no signs of leprosy or SAIDS before succumbing to septicemia during an unrelated procedure. B748 and B845 were both negative for SAIDS and leprosy at necropsy. Dr. Murphey-Corb's studies showed that A022 was STLV-III-positive and this virus was evidently cotransmitted to this group of rhesus monkeys along with the M. leprae inoculum (32).
Two rhesus were inoculated with M. leprae inoculum from SMM A015, which had natural leprosy and was STLV-III-negative by Western blot, virus culture and by RT-PCR analysis, but was STLV-I-positive (32). One of the A015 recipients (A125) developed LL leprosy within 20 months, but the second A015 recipient (A491) failed to develop leprosy within 38 months (Table 1 ) (20). Both A125 and A491 produced persisting high levels of anti-M. leprae-phenolic glycolipid-I (PGL-I) antibodies, suggesting that the M. leprae infection in A491 persisted, although no clinical signs of leprosy were visible in this animal ( Figures  2 and 3) . No antibodies to STLV-IIIDelta were present in A125 or initially in A491, of course, since the source of the Figure 4 . Percentages of CD4+ T cells (T-helper, Th) in peripheral blood of rhesus monkeys after experimental M. leprae inoculation. Mean ± 1 SE of normal rhesus monkeys (n = 58). Top Panel: Four animals inoculated at time zero with STLV-III (SIV-Delta) contaminated M. leprae isolate; 8664 and B988 developed leprosy and SAIDS; B845 developed neither disease but became serologically positive for SIV; and B748 had neither leprosy nor indications of SIV infection. Animals A491 and A125 were inoculated at time 0 with SIV-negative inocula; A491 was re-inoculated during month 38 (arrow) with SIV-containing isolate. {Figure reproduced (20) with permission from the publisher}. inoculum (SMM A015) was STLV-III-negative (32). However, rhesus A491 was re-inoculated after 38 months with M. leprae isolate from A022, resulting in the appearance of high levels of anti-STLV-IIIDelta antibodies documented by Western blot (Figure 3 Blood CD4+ T cell percentages were longitudinally studied in the six rhesus monkeys described in Table 1 (20). Significant reductions in CD4+ percentages were observed in animals 8664 and B988, which developed SAIDS and leprosy, but no reductions in CD4+ percentages were observed in monkeys B748 or B845, which failed to develop either SAIDS or leprosy (Figure 4) . A substantial significant reduction in CD4+ T cell percentages was also observed in rhesus A491 after inoculation with STLVIIIDelta-containing M. leprae inoculum from SMM A022 (Figure 4) . There was also a diminution in CD4+ T cell percentages over time in rhesus A125, although the CD4+ percentages remained within the low normal range ( Figure  4 ). In retrospect, loss of CD4+ T cells was expected, as observed, except for A125, since the source of A125's inoculum (SMM A015) was STLV-III-negative. However, SMM A015 was STLV-I-positive and this virus may have been responsible for the loss of CD4+ T cells.
CONCLUSIONS
The data indicated that rhesus monkeys infected with STLV-III-contaminated inoculum either developed both leprosy and SAIDS or neither disease and that the loss of CD4+ T cells paralleled the development of leprosy as well as SAIDS. No evidence was found that SMM-origin M. leprae differed from human M. leprae (1) . Rather, it was concluded that the presence of asymptomatic STLVIIIDelta (SIVDelta) infections in SMM rendered this species susceptible to leprosy (20). Moreover, the data suggest strongly that rhesus monkeys, a species that has been historically resistant to experimental leprosy (2), become susceptible to M. leprae disease secondary to coinfection with STLV-IIIDelta (SIVDelta) (20). We have published more recent data supporting this conclusion (7, 38) . Thus far, however, there has been little support from high leprosy-and HIV-endemic areas that there is a parallel situation between HIV infection and leprosy susceptibility in the human population.
EPILOGUE
The history described in this chapter would not be complete without mentioning that the remainder of the puzzle concerning the identity, origin and relationships between STLV-IIIDelta (SIVDelta) and STLV-IIImac (SIVmac) have been determined and reviewed (57) . To summarize, SIVmac, first isolated from macaques in 1985 at the New England Regional Primate Research Center (NERPRC) (53, 55, 56) , had its origin in SMM's at the California Regional Primate Research Center (CRPRC) where, in 1969, macaques were housed with SIV-positive SMM (57) . SIV-infected macaques at the CRPRC first showed SAIDS-like symptoms in 1969 and later in 1970 (58, 59) after being in contact with SIV-positive SMM's. SIV-infected macaques were inadvertently sent to other Primate Centers, including the NERPRC, where additional spread to other macaques took place. Thus, evidence suggests that both SIVDelta and SIVmac originated in SMM's and are closely related to one another and to HIV genetically (57) . Concurrent with our studies in SMM's, a similar natural retroviral infection (STLVIII AGM , now SIV AGM ) was reported in African green monkeys (AGM) (54, 60) 435-437 (1986) 
